Systemic Ang2 Upregulation Represents Potential Treatment Target for nAMD
Researchers consider the potential for Ang2 as a target for antiangiogenic agents in treatment of the disease.
Anti-VEGF Drugs
Pandemic Associated With Reduced Intravitreal Injections in France
Across France, fewer patients than expected underwent anti-VEGF treatments during COVID-19 lockdowns.
Ranibizumab Effective, Safe Long-Term Treatment for Diabetic Macular Edema, Study Says
The multicenter study confirms improvements in acuity and central retinal thickness.
Top Retina Highlights From the American Academy of Ophthalmology 2020 Conference
Researchers shared their latest retinal findings at the virtual conference.
Investigators: Ranibizumab Port Delivery System Durable, Effective
Study shows the time release device is comparable to monthly ranibizumab 0.5 mg injections.
Research Compares Imaging Technologies for Age-Related Macular Degeneration Monitoring
A study shows SD-OCT is appropriate in most cases.
Consistent Injections Better Maintain Visual Acuity, Study Says
Research shows how patients with AMD who are lost to follow-up face worse vision in time.
Ellipsoid Zone Integrity Improved During Intravitreal Injection Treatment
Photoreceptor integrity was also associated with best-corrected visual acuity.
Positive Effect of Anti-VEGF Therapy for nAMD Most Likely in First 2 Years of Treatment
Survival analyses may help overcome the limitations of current reporting practices.
Study Supports Efficacy of Faricimab Indications
The therapy “synergistically reduced inflammation, leakage, and neovascularization,” research shows.
-
Loading...
-
Loading...
Next post in AAO 2020 Retina In-depth
